Monthly Archives: February 2013

T-DM1 Receives FDA Approval

On February 22, 2012, the FDA approved Kadcyla, formerly know as T-DM1, for treatment of patients with HER2 positive breast cancer. Kadcyla is new type of targeted cancer treatment known as an antibody conjugate. It combines the antibody trastuzamab (Herceptin) … Continue reading

Posted in GCD-0032, T-DM1 & Systemic Treatment, Uncategorized | 6 Comments